Michael R. Hanley - US grants

Affiliations:

Amylin Pharmaceuticals, Hamilton, OH, United States

Tree Info Publications Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

We are testing a new system for linking grants to scientists.

The funding information displayed below comes from the NIH Research Portfolio Online Reporting Tools and the NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please sign in and mark grants as correct or incorrect matches.

Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.

High-probability grants

According to our matching algorithm, Michael R. Hanley is the likely recipient of the following grants.

Years	Recipients	Code	Title / Keywords	Matching score
1993 — 1995	Hanley, Michael Robert	R01Activity Code Description: To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies.	Mas Oncogene--Receptor Biology and Malignant Potential @ University of California Davis DESCRIPTION (Adapted from the Applicant's Abstract): The broad goal of this project is to elucidate the molecular mechanisms of signal recognition and transduction by the mammalian MAS oncogene in regulating normal growth or malignant transformation.Based on expression and functional analysis in heterologous cells, MAS has been proposed to function as a specialized receptor for the angiotensin peptide family. The specific aims of this proposal are as follows: (1) The mechanism of malignant transformation of mammalian cells. Studies are to determine the capability of MAS alone or in the presence of agonist peptides to elicit cell transformation, to assess the transforming activity of MAS- related genes, RTA and MRG, and to determine the transforming properties of MAS mutant construct. (2) The molecular characterization of the MAS oncoprotein and its receptor-coupled transduction events. In this specific aim, the applicant intends to characterize MAS protein with special emphasis on the evidence for post-translational modification and to answer the question of whether MAS is a functional angiotensin receptor. Show summary Hide summary	0.903